IFNG and cancer: Targeting the hypoxic conditions and HIF1α function in combination with anti-PD-L1 immunotherapy can overpass the adverse effect PD-L1, whether attributed to HIF1α or IFNγ in the TME, by enhancing the recognition of cancer cells and allowing effective cancer cell killing by the immune system.